Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan.
J Clin Pharm Ther. 2021 Feb;46(1):114-120. doi: 10.1111/jcpt.13262. Epub 2020 Sep 19.
Hypertension (HTN) and chronic kidney disease (CKD) are recognized as silent killers because they are asymptomatic conditions that contribute to the burden of multiple comorbidities. The achievement of a blood pressure (BP) goal can dramatically reduce the risks of CKD. In this study, we aimed to assess the effectiveness of pharmacist intervention on BP control in patients with CKD and evaluate the usefulness of home-based BP telemonitoring.
The terms "chronic kidney disease," "pharmacist," "BP" and "randomized controlled trial (RCT)" were used five databases to search for information regarding pharmacist intervention on BP control in patients with CKD. The inclusion criteria were as follows: (a) studies for adult patients with uncontrolled HTN and (b) studies with adequate data for meta-analysis. The primary outcome was an evaluation of achievement of BP goal in patients with CKD. The secondary outcome was usefulness of home-based BP telemonitoring by pharmacists in patients with CKD.
Six RCTs were identified and included in the meta-analysis with a total of 2573 patients (mean age 66.0 years and 63.9% male). Pharmacist interventions resulted in significantly better BP control vs usual care (OR = 1.53, 95% CI = 1.15-2.04, P < .01). Pharmacist interventions using home-based BP telemonitoring were significantly superior to control/usual care (OR = 2.03, 95% CI = 1.49-2.77, P < .01), whereas pharmacist interventions without home-based BP telemonitoring did not significantly improve BP control compared to that with control/usual care (OR = 1.30, 95% CI = 0.97-1.75, P = .08). Home-based BP telemonitoring supported team-based care for HTN in these studies. In addition, patient self-monitoring with telemedicine devices might enhance patients' abilities to manage their condition by pharmacist instruction.
The findings of this meta-analysis showed that pharmacist interventions with home-based BP telemonitoring improve BP control among adult patients with CKD.
高血压(HTN)和慢性肾脏病(CKD)被认为是“沉默的杀手”,因为它们是无症状的疾病,会导致多种合并症的负担。实现血压(BP)目标可以显著降低 CKD 的风险。在这项研究中,我们旨在评估药剂师干预对 CKD 患者血压控制的效果,并评估基于家庭的 BP 远程监测的有用性。
使用五个数据库中的“慢性肾脏病”、“药剂师”、“BP”和“随机对照试验(RCT)”等术语来搜索有关药剂师干预 CKD 患者血压控制的信息。纳入标准如下:(a)针对未控制的 HTN 成年患者的研究;(b)具有足够数据进行荟萃分析的研究。主要结局是评估 CKD 患者的 BP 目标达标情况。次要结局是药剂师在 CKD 患者中进行基于家庭的 BP 远程监测的有用性。
确定了六项 RCT 并将其纳入荟萃分析,共有 2573 名患者(平均年龄 66.0 岁,63.9%为男性)。与常规护理相比,药剂师干预可显著改善血压控制(OR=1.53,95%CI=1.15-2.04,P<.01)。使用基于家庭的 BP 远程监测的药剂师干预明显优于对照组/常规护理(OR=2.03,95%CI=1.49-2.77,P<.01),而不使用基于家庭的 BP 远程监测的药剂师干预与对照组/常规护理相比并未显著改善血压控制(OR=1.30,95%CI=0.97-1.75,P=0.08)。在这些研究中,基于家庭的 BP 远程监测支持团队对 HTN 的治疗。此外,患者通过远程医疗设备进行自我监测,通过药剂师的指导,可能会增强患者管理病情的能力。
这项荟萃分析的结果表明,基于家庭的 BP 远程监测的药剂师干预可改善 CKD 成年患者的血压控制。